The results of the present study are encouraging with regards to the cost-effectiveness of ethyl-EPA in the treatment of BD. However, the ultimate test of the cost-effectiveness of any intervention is how it performs in ordinary care. We could not test this directly as we do not have any observational datasets on the use of ethyl-EPA from routine clinical practice but this should be the next step in future studies. Acknowledgments Cost data used in the study were based on earlier calculations by Francis Swaray while an MSc student at City Inhibitors,research,lifescience,medical University and on placement at the Institute of Psychiatry. Professor Mireia Jofre-Bonet at City University supervised the research.
Footnotes Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest statement: The authors declare that
they have no conflicts of interests regarding the content of this research paper. Contributor Information Nadir Cheema, University College London, CORE, Abexinostat Department of Clinical Health Inhibitors,research,lifescience,medical Psychology, 1-19 Torrington Place, London WC1E 7HB, UK. Sophia Frangou, Kings College London, Institute of Psychiatry, London, UK. Paul McCrone, Kings College London, Institute of Psychiatry, London, UK.
Obsessive–compulsive disorder (OCD) is a disabling disorder often under recognized and is all too often refractory to treatment. Inhibitors,research,lifescience,medical The evidence base supports the use of cognitive behavioural therapy (CBT) with exposure and response prevention as first-line treatment with concomitant treatment with selective serotonin reuptake Inhibitors,research,lifescience,medical inhibitor (SSRI) antidepressants for more severe or therapy-unresponsive cases. Treatment with clomipramine and antipsychotic medication is recommended for Inhibitors,research,lifescience,medical the most treatment-resistant cases. Despite these manoeuvres, some 40% of cases are treatment resistant, and many become disillusioned with the psychiatric services
and are lost to follow up [Heyman et al. 2006; Abramowitz et al. 2009; Fineberg and Brown, 2011]. The treatment of last resort has been psychosurgery, which can result in substantial improvement in some 50% of cases without significant adverse effects [Jung et al. 2006]. More recently, deep brain stimulation has shown promise [de Koning et al. 2011], but the procedure is still experimental Cediranib (AZD2171) and is not widely available. Thus there remains a need to further develop minimally invasive treatment options for refractory OCD. In this regard there is a small literature supporting the use of opiates in the treatment of refractory OCD [Shapira et al. 1997; Warneke, 1997; Goldsmith et al. 1999; Koran et al. 2005]. In this case series of seven patients with severe, treatment-resistant OCD we present our experience in using buprenorphine to augment antidepressant treatment of their OCD. Methods The patients were recruited from a standard psychiatric outpatient clinic.